Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma

Johanna Chiffelle,David Barras,Rémy Pétremand,Angela Orcurto,Sara Bobisse,Marion Arnaud,Aymeric Auger,Blanca Navarro Rodrigo,Eleonora Ghisoni,Christophe Sauvage,Damien Saugy,Alexandra Michel,Baptiste Murgues,Noémie Fahr,Martina Imbimbo,Maria Ochoa de Olza,Sofiya Latifyan,Isaac Crespo,Fabrizio Benedetti,Raphael Genolet,Lise Queiroz,Julien Schmidt,Krisztian Homicsko,Stefan Zimmermann,Olivier Michielin,Michal Bassani-Sternberg,Lana E. Kandalaft,Urania Dafni,Jesus Corria-Osorio,Lionel Trueb,Denarda Dangaj Laniti,Alexandre Harari,George Coukos
DOI: https://doi.org/10.1016/j.immuni.2024.08.014
IF: 32.4
2024-10-09
Immunity
Abstract:Adoptive cell therapy (ACT) using in vitro expanded tumor-infiltrating lymphocytes (TILs) can be curative in melanoma but has inconsistent clinical responses. Chiffelle, Barras, et al. track TIL clonotypes in melanoma patients through ACT therapy and provide insight into the profiles and dynamics of tumor-specific clonotypes associated with clinical response and features related to non-responsiveness.
immunology
What problem does this paper attempt to address?